Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on medicines affecting cellular metabolism. It develops and sells oral treatments for blood disorders, including pyruvate kinase deficiency and thalassemia, and it has also worked on therapies for rare genetic diseases and certain cancers. Its customers are mainly patients, physicians and healthcare systems that use its prescription medicines, and its research centres on red blood cell health and metabolic pathways.
On this site Agios Pharmaceuticals, Inc. appears as a stock on the London Stock Exchange (UK), code 0HB0, with prices in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #1909 of 3788 on the London Stock Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
73/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average18.8%
From 52-week high-13.1%
MomentumStrong
75/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return0.2%
6-month return51.5%
Stability (higher is calmer)Weak
34/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)59.0%
Worst drawdown, 1 year (smaller is calmer)-30.5%
LiquidityWeak
12/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.01M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 24.47 – 44.98Daily closes, split-adjusted
Signals
50-day average33.64
200-day average31.62
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)1.37
Technical summary
Daily
Strongly bullish
11 bullish · 1 neutral · 3 bearish
Weekly
Strongly bullish
6 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
1 bullish · 0 neutral · 0 bearish
Moving averages (daily)
SMA 10
35.03
Bullish
EMA 10
35.56
Bullish
SMA 20
33.46
Bullish
EMA 20
34.45
Bullish
SMA 50
33.64
Bullish
EMA 50
33.86
Bullish
SMA 100
34.43
Bullish
EMA 100
33.36
Bullish
SMA 200
31.62
Bullish
EMA 200
–
n/a
Oscillators (daily)
RSI (14)
65.99
Neutral
MACD (12, 26)
1.05
Bullish
Momentum (12)
17.56
Bullish
Stochastic %K (14)
95.44
Bearish
Williams %R (14)
-4.56
Bearish
CCI (20)
124.0
Bearish
Pivot points (classic, last session)
S3
35.79
S2
36.15
S1
36.85
Pivot
37.21
R1
37.91
R2
38.27
R3
38.97
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in USD. Educational only, not financial advice.
